血脂异常
医学
叙述性评论
临床试验
重症监护医学
他汀类
生物信息学
内科学
肥胖
生物
作者
Hussain Sohail Rangwala,Hareer Fatima,Faiza Riaz,Burhanuddin Sohail Rangwala
标识
DOI:10.1016/j.cpcardiol.2024.102516
摘要
The study "Inclisiran siRNA technology in the management of dyslipidemia: A narrative review of clinical trials" evaluates inclisiran's efficacy and safety in reducing LDL cholesterol levels across diverse patient populations. Twelve clinical trials were reviewed, demonstrating consistent LDL-C reduction, even in statin intolerance or resistance cases, with sustained efficacy observed over various durations, some extending up to four years. Inclisiran exhibited a favorable safety profile, suggesting its potential as a well-tolerated treatment option. Despite promising findings, the limitations include the short duration of some trials and the exclusion of non-English language studies, warranting further research. Future studies should focus on the long-term safety and efficacy in diverse patient populations and explore the broader clinical implications of inclisiran. Although inclisiran shows promise in dyslipidemia management, comprehensive research is needed to understand its full potential in cardiovascular medicine.
科研通智能强力驱动
Strongly Powered by AbleSci AI